For the treatment of both Type-1 and Type-2 diabetes, Oral-Recosulin can be used. This buccal insulin spray is developed by Shreya Life Science Pvt Ltd’s US collaborator Generex Biotechnology. Buccal spray delivers insulin through buccal mucosa, directly to the vascular system without entering the lungs.
Shreya Life Science Pvt Ltd, is in charge of marketing the device in the country.
It can be added that India is considered as the diabetes capital in the world. With a 40-million diabetes population, the Indian diabetic market is around Rs 1,722.7 crore. According to a WHO report, diabetes is growing by 40% in developed countries and 170% in developing countries.